A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://www.ncbi.nlm.nih.gov/pubmed/23860641
http://dx.doi.org/10.1007/s10637-013-0001-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://www.ncbi.nlm.nih.gov/pubmed/23860641
http://dx.doi.org/10.1007/s10637-013-0001-5

Ejemplares similares